

DAFTAR PUSTAKA

- Adebisi, Y. A., Jimoh, N. D., Ogunkola, I. O., Uwizeyimana, T., Olayemi, A. H., Ukor, N. A., & Lucero-Prisno, D. E. (2021). The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries. *Tropical Medicine and Health*, 49(1), 51. <https://doi.org/10.1186/s41182-021-00344-w>
- Al Amin. M. (2017). Klasifikasi Kelompok Umur Manusia Berdasarkan Analisis Dimensi Fraktal Box Counting Dari Citra Wajah Dengan Deteksi Tepi Canny. *Jurnal Ilmiah Matematika*, 2(6).
- Al Mutair, A., Layqah, L., Alhassan, B., Alkhalifah, S., Almossabeh, M., AlSaleh, T., AlSulaiman, Z., Alatiyyah, Z., Almusalami, E. M., Al-Jamea, L. H., Woodman, A., Hajissa, K., Alhumaid, S., & Rabaan, A. A. (2022). Estimated cost of treating hospitalized COVID-19 patients in Saudi Arabia. *Scientific Reports*, 12(1). <https://doi.org/10.1038/s41598-022-26042-z>
- Alamer, A., Almutairi, A. R., Halloush, S., Al-jedai, A., Alrashed, A., AlFaifi, M., Mohzari, Y., Almutairi, M., AlHassar, F., Howaidi, J., Almutairi, W., Abraham, I., & Alkhatib, N. (2023). Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals. *Saudi Pharmaceutical Journal*, 31(4), 510–516. <https://doi.org/10.1016/j.jsps.2023.02.003>
- Ambarwati, W. (2021). Pembiayaan Pasien COVID-19 dan Dampak Keuangan terhadap Rumah Sakit yang Melayani Pasien COVID-19 di Indonesia Analisis Periode Maret 2020-Desember 2020 COVID-19 Patient Payment and Financial Implication on Hospitals Serving COVID-19 Patients in Indonesia. *Ekonomi Kesehatan Indonesia*, 6(1).
- Amir, H., Sudarman, S., Asfar, A., & Batara, A. S. (2020). Covid19 Pandemic: Management and Global Response. *JURNAL KESEHATAN LINGKUNGAN*, 12(1si), 121. <https://doi.org/10.20473/jkl.v12i1si.2020.121-128>
- Andayani, T. M. (2013). *Farmakoekonomi Prinsip dan Metodologi* (Vol. 1). Bursa Ilmu.
- Andrafarm. (2022). *Sebaran Harian Virus Corona Provinsi Di Yogyakarta*. https://m.andrafarm.com/_andra.php?_i=daftar-co19-provinsi&noneg=5&urut=2&asc=01100000000
- Anggun Wulandari, Fauzie Rahman, Nita Pujiarti, & Ayu Riana Sari. (2020). Hubungan Karakteristik Individu dengan Pengetahuan tentang Pencegahan Coronavirus Disease 2019 pada Masyarakat di Kalimantan Selatan. *Jurnal Kesehatan Masyarakat Indonesia*, 15(1).
- Aranow, C. (2011). Vitamin D and the Immune System. *J Investig Med*, 59(6).
- Bartsch, S. M., Ferguson, M. C., McKinnell, J. A., O'shea, K. J., Wedlock, P. T., Siegmund, S. S., & Lee, B. Y. (2020). The potential health care costs and

- resource use associated with COVID-19 in the United States. *Health Affairs*, 39(6), 927–935. <https://doi.org/10.1377/hlthaff.2020.00426>
- Behboodikhah, H., Shorafa, E., Karimzadeh, I., Moghadami, M., Shahmohammadi, J., Bayati, M., Keshavarz, K., & Negahdaripour, M. (2022). Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz. *Iranian Journal of Science and Technology, Transactions A: Science*, 46(5), 1339–1347. <https://doi.org/10.1007/s40995-022-01351-0>
- Bergman, P. (2021). The link between vitamin D and COVID-19: distinguishing facts from fiction. *Journal of Internal Medicine*, 289(1), 131–133. <https://doi.org/10.1111/joim.13158>
- Boehmer, T., DeVies, J., Caruso, E., van Santen, K., Tang, S., & Black, C. (2020). Changing Age Distribution of the COVID-19 Pandemic — United States, May–August 2020. *Morbidity and Mortality Weekly Report*, 69, 1404–1409.
- Bootman, J. L., Towsend, R. J., & McGhan, W. F. (1996). *Principle of Pharmacoeconomics* (2nd ed.). Appleton and Lange.
- BPOM RI. (2022). *Informaritorium Obat COVID-19 di Indonesia* (4th ed.). Badan Pengawas Obat dan Makanan Republik Indonesia.
- Brown, A. J., Won, J. J., Graham, R. L., Dinnon, K. H., Sims, A. C., Feng, J. Y., Cihlar, T., Denison, M. R., Baric, R. S., & Sheahan, T. P. (2019). Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. *Antiviral Research*, 169, 104541. <https://doi.org/10.1016/j.antiviral.2019.104541>
- Budi, A. P., & Nafisah, U. (2023). PERHITUNGAN UNIT COST PADA PASIEN COVID 19 DI INSTALASI RAWAT INAP DI RS. ROEMANI MUHAMMADIYAH SEMARANG. *Jurnal Ilmiah Rekam Medis Dan Informatika Kesehatan*, 13(1). <https://doi.org/https://doi.org/10.47701/infokes.v13i1.2530>
- Burhan, E., Dwi Susanto, A., Isbaniah, F., Aman Nasution, S., Ginanjar, E., Wicaksono Pitoyo, C., Susilo, A., Firdaus, I., Santoso, A., Arifa Juzar, D., Kamsul Arif, S., Lolong Wulung, N. G., Muchtar, F., Pulungan, A. B., Ambara Sjakti, H., Prawira, Y., Dwi Putri TIM PENYUSUN Erlina Burhan, N., Adityaningsih, D., Fahrial Syam, A., ... Mayung Sambo, C. (2020). *Pedoman Tatalaksana COVID-19 Edisi 3*.
- Burhan, E., Dwi Susanto, A., Isbaniah, F., Aman Nasution, S., Ginanjar, E., Wicaksono Pitoyo, C., Susilo, A., Firdaus, I., Santoso, A., Arifa Juzar, D., Kamsul Arif, S., Lolong Wulung, N. G., Muchtar, F., Pulungan, A. B., Basarah Yanuarso, P., Ambara Sjakti, H., Prawira, Y., Dwi Putri TIM PENYUSUN Erlina Burhan, N., Adityaningsih, D., ... Dharmawan, I. (2022). *Pedoman Tatalaksana COVID-19 Edisi 4*.
- Byford, S., Torgerson, D. J., & Raftery, J. (2000). *Economic Note Cost of illness studies*.

- Cate, H. (2021). Surviving Covid-19 with Heparin? *New England Journal of Medicine*, 385(9), 845–846. <https://doi.org/10.1056/NEJMe2111151>
- Centers for Disease Control and Prevention. (2020). *Centers for Disease Control and Prevention. Interim US guidance for risk assessment and public health management of healthcare personnel with potential exposure in a healthcare setting to patients with coronavirus disease (COVID-19)*. <https://www.Cdc.Gov/Coronavirus/2019-Ncov/Hcp/Guidance-Risk-Assesment-Hcp.Html>.
- Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases*, 40(5), 373–383. [https://doi.org/10.1016/0021-9681\(87\)90171-8](https://doi.org/10.1016/0021-9681(87)90171-8)
- Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X. (2021). Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. *Frontiers in Pharmacology*, 12. <https://doi.org/10.3389/fphar.2021.683296>
- Christian Yong, B. J. (2021). Penggunaan Parasetamol pada Covid-19. *Cermin Dunia Kedokteran*, 48(7), 412. <https://doi.org/10.55175/cdk.v48i7.1457>
- COVID-19 Treatment Guidelines Panel. (2020). *COVID-19 Treatment Guidelines*. <https://www.COVID19treatmentguidelines.nih.gov/>.
- Dana, P., Sadoughi, F., Hallajzadeh, J., Asemi, Z., Mansournia, M. A., Yousefi, B., & Momen-Heravi, M. (2020). An Insight into the Sex Differences in COVID-19 Patients: What are the Possible Causes? *Prehospital and Disaster Medicine*, 35(4), 438–441. <https://doi.org/10.1017/S1049023X20000837>
- de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016). SARS and MERS: Recent insights into emerging coronaviruses. In *Nature Reviews Microbiology* (Vol. 14, Issue 8, pp. 523–534). Nature Publishing Group. <https://doi.org/10.1038/nrmicro.2016.81>
- Delvi, T., Geografi, L., & Ritawany Sinaga, C. (2022). STUDI RASIONALITAS PENGGUNAAN OBAT FAVIPIRAVIR PADA PASIEN COVID-19 DI RSUD HARAPAN INSAN SENDAWAR KABUPATEN KUTAI BARAT TAHUN 2021. *Pharmaceutical Journal of Islamic Pharmacy*, 6(2), 2021. <https://doi.org/10.21111/pharmasipha.v6i12>
- Depkes RI. (2009). *Klasifikasi Umur Menurut Kategor*.
- Depkes RI. (2013). *Pedoman Penerapan Kajian Farmakoekonomi*.
- di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. In *International Journal of Environmental Research and Public Health* (Vol. 17, Issue 8). MDPI AG. <https://doi.org/10.3390/ijerph17082690>

- Dipiro C, Wells B, Schwinghammer T, & Dipiro J. (2014). *Pharmacotherapy Handbook* (9th ed.). McGraw-Hill Education.
- Doi, Y., Kondo, M., & Matsuyama, A. (2020). *Preliminary report of the favipiravir observational study in Japan (2020/5/15)*. 2020.
- Edoka, I., Fraser, H., Jamieson, L., Meyer-Rath, G., & Mdewa, W. (2021). Inpatient Care Costs of COVID-19 in South Africa's Public Healthcare System. *International Journal of Health Policy and Management*. <https://doi.org/10.34172/ijhpm.2021.24>
- Esposito, S., Noviello, S., & Pagliano, P. (n.d.). Update on treatment of COVID-19: ongoing studies between promising and disappointing results. *Le Infezioni in Medicina*, 28(2), 198–211.
- Ghaffari Darab, M., Keshavarz, K., Sadeghi, E., Shahmohamadi, J., & Kavosi, Z. (2021). The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran. *BMC Health Services Research*, 21(1). <https://doi.org/10.1186/s12913-021-06126-8>
- Giusman, R., & Nurwahyun, A. (2022). Biaya Pengobatan Pasien Rawat Inap COVID-19 di Rumah Sakit X Tahun 2021. *Jurnal Ekonomi Kesehatan Indonesia*, 7(2).
- Giusman, R., & Nurwahyuni, A. (2022). BIAYA PENGobatan PASIEN RAWAT INAP COVID-19 DI RUMAH SAKIT X TAHUN 2021. *Jurnal Ekonomi Kesehatan Indonesia*, 7(2), 96. <https://doi.org/10.7454/eki.v7i2.5797>
- Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., ... Zhong, N. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*, 382(18), 1708–1720. <https://doi.org/10.1056/nejmoa2002032>
- Hairani, R. (2022). *Kemenkes Pastikan Percepat Bayar Klaim Layanan Covid-19*. <https://Rri.Co.Id/Humaniora/Kesehatan/1356988/Kemenkes-Pastikan-Percepat-Bayar-Klaim-Layanan-Covid-19>.
- Halimbar, A., Lorensia, A., & Ramadani, D. (2023). Cost-Effectiveness Analysis Of Remdesivir And Favipiravir Therapy For The Treatment Of Covid-19 In Adult Patients At Haji Regional General Hospital, East Java Province. *Jurnal Scientia*, 12(1).
- Hijratul Muhammadiyah. (2021). *Obesity and Severity COVID-19: Literature Review Study*.
- Hirashima, Arai Tsuyoshi, & Kitajima Heita. (2020). Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study. *Journal of Infection and Chemotherapy*, 27, 76–82.
- Hirashima, T., Arai, T., Kitajima, H., Tamura, Y., Yamada, T., Hashimoto, S., Morishita, H., Minamoto, S., Kawashima, K., Kashiwa, Y., Kameda, M., Takeshita, T., Suzuki, H., Matsuoka, H., Yamaguchi, S., Tanaka, T., & Nagai, T. (2021). Factors significantly associated with COVID-19 severity

- in symptomatic patients: A retrospective single-center study. *Journal of Infection and Chemotherapy*, 27(1), 76–82. <https://doi.org/10.1016/j.jiac.2020.09.022>
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020a). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020b). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- Ismaila, H., Asamani, J. A., Lokossou, V. K., Oduro-Mensah, E., Nabyonga-Orem, J., & Akoriyea, S. K. (2021). The cost of clinical management of SARS-COV-2 (COVID-19) infection by level of disease severity in Ghana: a protocol-based *cost of illness* analysis. *BMC Health Services Research*, 21(1). <https://doi.org/10.1186/s12913-021-07101-z>
- Iyer, S., Reddy, K. N., Shah, J., Chowdhury, M., Yerrapalem, N., Pasalkar, N., & Jedge, P. P. (2022). Direct Medical Cost Analysis of Indian COVID-19 Patients Requiring Critical Care Admission. *Indian Journal of Critical Care Medicine*, 25(10), 1120–1125. <https://doi.org/10.5005/jp-journals-10071-23991>
- Jamini Theresia. (2021). Gambaran Lama Hari Rawat Inap Pasien Covid-19 Berdasarkan Karakteristik Demografi, Klinis dan Hasil Laboratorium Pasien di Ruang Perawatan Covid-19 RSUD H. Boejasin Pelaihari Tahun 2021. *Jurnal Penelitian UPR: Kaharati*, 1(2), 45–53.
- Jeck, J., Jakobs, F., Kron, A., Franz, J., Cornely, O. A., & Kron, F. (2022). A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital. *Infection*, 50(1), 191–201. <https://doi.org/10.1007/s15010-021-01685-8>
- Jin, H., Wang, H., Li, X., Zheng, W., Ye, S., Zhang, S., Zhou, J., & Pennington, M. (2021). Economic burden of COVID-19, China, January–March, 2020: a cost-of-illness study. *Bulletin of the World Health Organization*, 99(2), 112–124. <https://doi.org/10.2471/BLT.20.267112>
- Jin, Y. H., Cai, L., Cheng, Z. S., Cheng, H., Deng, T., Fan, Y. P., Fang, C., Huang, D., Huang, L. Q., Huang, Q., Han, Y., Hu, B., Hu, F., Li, B. H., Li, Y. R., Liang, K., Lin, L. K., Luo, L. S., Ma, J., ... Wang, X. H. (2020). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). In *Military Medical Research* (Vol. 7, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s40779-020-0233-6>

- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. *International Journal of Infectious Diseases*, 102, 501–508. <https://doi.org/10.1016/j.ijid.2020.10.069>
- Juwita Sri Sil, Anggraini Dian, & Kurniawati Dewi. (2022). Gambaran Karakteristik Pasien COVID-19 di Rumah Sakit Otak DR. Mohammad Hatta Bukitinggi. *Journal Ilmu Kesehatan Afyah*, IX.
- Kao, K. C., Chiu, L. C., Hung, C. Y., Chang, C. H., Yang, C. T., Huang, C. C., & Hu, H. C. (2017). Coinfection and Mortality in Pneumonia-Related Acute Respiratory Distress Syndrome Patients with Bronchoalveolar Lavage: A Prospective Observational Study. *Shock*, 47(5), 615–620. <https://doi.org/10.1097/SHK.0000000000000802>
- Karyono, D. R., & Wicaksana, A. L. (2020). Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *Journal of Community Empowerment for Health*, 3(2), 77. <https://doi.org/10.22146/jcoemph.57325>
- Karyono, D. R., Wicaksana, A. L., & Wicaksana, A. L. (2020). Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *Journal of Community Empowerment for Health*, 3(2), 77. <https://doi.org/10.22146/jcoemph.57325>
- Kemkes. (2020). *Petunjuk Teknis Klaim Penggantian Biaya Perawatan Pasien Penyakit Infeksi Emerging Tertentu Bagi Rumah Sakit yang Menyelenggarakan Pelayanan Corona Virus Disease 2019 (COVID-19)*. https://covid19.kemkes.go.id/download/KMK_No_HK_01_07_MENKES_238_2020_ttg_JUKNIS_Penggantian_Biaya_Pasien_Infeksi_Emerging_Tertentu.pdf
- Kementerian Kesehatan. (2021). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/5671/2021 Tentang Manajemen Klinis Tata Laksana Corona Virus Disease 2019 (COVID-19) Di Fasilitas Pelayanan Kesehatan*.
- Khaerunnisa, R., Rumana, N. A., Yulia, N., & Fannya, P. (2022). Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021. *Jurnal Manajemen Informasi Kesehatan Indonesia*, 10(1), 72. <https://doi.org/10.33560/jmiki.v10i1.390>
- Khandehroo, M., Dorri, M., Paykani, T., Khajavi, A., Joshani-Kheibari, M., & Esmaeili, R. (2022). Direct Inpatient Cost and Payments of COVID-19 in Iran: Quantile Regression Analysis. *Medical Journal of the Islamic Republic of Iran*. <https://doi.org/10.47176/mjiri.36.101>
- Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. In *Nature Reviews Immunology* (Vol. 16, Issue 10, pp. 626–638). Nature Publishing Group. <https://doi.org/10.1038/nri.2016.90>

- Kuehn, B. M. (2021). Antibiotic Use in UK's COVID-19 Patients Often Unnecessary. *JAMA*, 326(3), 214. <https://doi.org/10.1001/jama.2021.10458>
- Kunz, R., & Minder, M. (2020). COVID-19 pandemic: palliative care for elderly and frail patients at home and in residential and nursing homes. *Swiss Medical Weekly*. <https://doi.org/10.4414/smww.2020.20235>
- Lam, S., Lombardi, A., & Ouanounou, A. (2020). COVID-19: A review of the proposed pharmacological treatments. *Eur J Pharmacol*, 1.
- Lemeshow, S. (1997). *Besar Sampel Dalam Penelitian Kesehatan (Terjemahan)*. Gadjah Mada University Press.
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., ... Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *New England Journal of Medicine*, 382(13), 1199–1207. <https://doi.org/10.1056/nejmoa2001316>
- Li, X. Z., Jin, F., Zhang, J.-G., Deng, Y.-F., Shu, W., Qin, J.-M., Ma, X., & Pang, Y. (2020). Treatment of coronavirus disease 2019 in Shandong, China: a cost and affordability analysis. *Infectious Diseases of Poverty*, 9(1), 78. <https://doi.org/10.1186/s40249-020-00689-0>
- Liza, A. Y., Laksmitawati, D. R., Sarnianto, P., & Anggeraini, S. D. (2022). ANALISIS KLAIM PEMBIAYAAN KEMENKES DAN BIAYA RIIL RS PADA COVID-19 DI RSUD CEMPAKA PUTIH JAKARTA. *Jurnal Kesehatan*, 13(2), 172–186. <https://doi.org/10.38165/jk.v13i2.323>
- Mangiafico, M., Caff, A., & Costanzo, L. (2022). The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. *Journal of Clinical Medicine*, 11(11), 3099. <https://doi.org/10.3390/jcm11113099>
- Mazidah Zulfa, Yasin Nanang Munif, & Kristina Susi Ari. (2019). Analisis Biaya Penyakit Stroke Pasien Jaminan Kesehatan Nasional di RSUD Blambangan Banyuwangi. *JMPF*, 9(2), 76–87.
- Mehta, O. P., Bhandari, P., Raut, A., Kacimi, S. E. O., & Huy, N. T. (2021). Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. In *Frontiers in Public Health* (Vol. 8). Frontiers Media S.A. <https://doi.org/10.3389/fpubh.2020.582932>
- Memirie, S. T., Yigezu, A., Zewdie, S. A., Mirkuzie, A. H., Bolongaita, S., & Verguet, S. (2022). Hospitalization costs for COVID-19 in Ethiopia: Empirical data and analysis from Addis Ababa's largest dedicated treatment center. *PLoS ONE*, 17(1 January). <https://doi.org/10.1371/journal.pone.0260930>
- Miethke-Morais, A., Cassenote, A., Piva, H., Tokunaga, E., Cobello, V., Rodrigues Gonçalves, F. A., dos Santos Lobo, R., Trindade, E., Carneiro D'Albuquerque, L. A., & Haddad, L. (2021). COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors. *The*

- Brazilian Journal of Infectious Diseases*, 25(4), 101609.
<https://doi.org/10.1016/j.bjid.2021.101609>
- Millenia, N. T. (2022). *Kajian pustaka efektivitas dan efek samping N-acetylcysteine pada pasien Covid-19* [Undergraduate thesis]. Widya Mandala Surabaya Catholic University.
- Nguyen, M. H., Lim, J. K., Burak Ozbay, A., Fraysse, J., Liou, I., Meyer, N., Dusheiko, G., & Gordon, S. C. (2019). Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. *Hepatology*, 69(3), 959–973. <https://doi.org/10.1002/hep.30246>
- Niu, S., Tian, S., Lou, J., Kang, X., Zhang, L., Lian, H., & Zhang, J. (2020). Clinical characteristics of older patients infected with COVID-19: A descriptive study. *Archives of Gerontology and Geriatrics*, 89. <https://doi.org/10.1016/j.archger.2020.104058>
- Nugraha, R. R., Pratiwi, M. A., Al-Faizin, R. E., Permana, A. B., Setiawan, E., Farianty, Y., Komaryani, K., & Thabrany, H. (2022). Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims data of COVID-19 in 2020-2021. *Health Economics Review*, 12(1). <https://doi.org/10.1186/s13561-022-00392-w>
- Nursalam. (2017). *Metodologi Penelitian Ilmu Keperawatan* (4th ed.). Salemba Medika.
- PAPDI. (2020). *Pedoman Tatalaksana Covid-19*. <https://www.papdi.or.id/Pdfs/938/Pedoman%20Tatalaksana%20COVID-19%20edisi%202.Pdf>
- Perhimpunan Dokter Paru Indonesia (PDPI). (2022). *Pedoman Tatalaksana COVID-19* (4th ed.).
- Putri, A., & Rostinawati, T. (2022). REVIEW ARTIKEL : Penggunaan Antivirus pada Pasien Covid-19. *Farmaka*, 20(2).
- Rahmandani, A., Sarnianto, P., Anggriani, Y., & Purba, F. D. (2021). Analisis Efektivitas Biaya Penggunaan Obat Antivirus Oseltamivir dan Favipiravir pada Pasien Covid-19 Derajat Sedang di Rumah Sakit Sentra Medika Cisolak Depok. *Majalah Farmasetika*, 6(1), 133–144.
- Rahmawati, C., Nurbaety, B., Qiyaam, N., Dini, S., & Maftuhah, L. (2022). Cost of illness for COVID-19 inpatients in West Nusa Tenggara, Indonesia. *Pharmacy Education*, 22(2), 66–69. <https://doi.org/10.46542/pe.2022.222.6669>
- Ramacciotti, E., Barile Agati, L., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., de Oliveira, C. C. C., Lins dos Santos, J., Volpiani, G. G., Sobreira, M. L., Joviliano, E. E., Bohatch Júnior, M. S., da Fonseca, B. A. L., Ribeiro, M. S., Dusilek, C., Itinose, K., Sanches, S. M. V., de Almeida Araujo Ramos, K., de Moraes, N. F., Tierno, P. F. G. M. M., ... Barbosa Santos, M. V. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. *The Lancet*, 399(10319), 50–59. [https://doi.org/10.1016/S0140-6736\(21\)02392-8](https://doi.org/10.1016/S0140-6736(21)02392-8)

- Roffman, C. E., Buchanan, J., & Allison, G. T. (2016). Charlson Comorbidities Index. *Journal of Physiotherapy*, 62(3), 171. <https://doi.org/10.1016/j.jphys.2016.05.008>
- Rotter, T., Kinsman, L., James, E. L., Machotta, A., Gothe, H., Willis, J., Snow, P., & Kugler, J. (2010). Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. *Cochrane Database of Systematic Reviews*. <https://doi.org/10.1002/14651858.CD006632.pub2>
- Ruhyat, E. (2021). PERILAKU MEROKOK DI MASA COVID 19. *Jurnal Sehat Masada*, 15.
- Rumi, A., Ambianti, N., & Arbi, D. S. (2022). PATTERNS OF MEDICINE USE FOR COVID-19 PATIENTS AT UNDATA HOSPITAL PALU. *Jurnal Administrasi Kesehatan Indonesia*, 10(1), 99–110. <https://doi.org/10.20473/jaki.v10i1.2022.99-110>
- Sama, I. E., Ravera, A., Santema, B. T., Van Goor, H., Ter Maaten, J. M., Cleland, J. G., Rienstra, M., Friedrich, A. W., Samani, N. J., & Dickstein, K. (2022). Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. *European Heart Journal*, 41(19), 1810–1817.
- Sanchez, L. (2005). *Pharmacoeconomics: Principles, Methods and Applications in Dipiro, J., Talbert, R., Yee, G., Matzke, G., Wells, B., Posey, L. Pharmacotherapy A Pathophyidiologic Approach*. McGraw- Hill.
- Segel, J. E. (2006). *Cost-of-Illness Studies-A Primer*. <https://www.researchgate.net/publication/253434922>
- Skarayadi Oskar, Ambarsundari, Vikasari Suci, Ramadhan Muhamad Syahrul, & Sutandi Tatan. (2023). COST OF ILLNESS ANALYSIS OF COVID-19 PATIENTS WITH COMORBID TYPE 2 DIABETES IN A HOSPITAL IN BANDUNG. *Pharmacoscript*, 6(1).
- Susilo, A., Martin Rumende, C., Pitoyo, C. W., Djoko Santoso, W., Yulianti, M., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Khie Chen, L., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O., & Yuniastuti, E. (2020). TINJAUAN PUSTAKA. In *Jurnal Penyakit Dalam Indonesia* | (Vol. 7, Issue 1). <https://www.ncbi.nlm.nih.gov/nucore/>
- Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S., Catton, M., Cowie, B., Tong, S. Y. C., Lewin, S. R., & Kedzierska, K. (2020). Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. In *Nature Medicine* (Vol. 26, Issue 4, pp. 453–455). Nature Research. <https://doi.org/10.1038/s41591-020-0819-2>
- Tian, R., Wu, W., Wang, C., Pang, H., Zhang, Z., Xu, H., Luo, Q., Gao, P., Shi, J., Li, W., Qian, H., Guo, F., Li, T., Liu, Z., Wang, J., Zhou, X., Qin, Y., Yan, X., & Zhang, S. (2020). Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-

- center retrospective case control study. *Scientific Reports*, 10(1).
<https://doi.org/10.1038/s41598-020-74465-3>
- Tian, S., Hu, N., Lou, J., Chen, K., Kang, X., Xiang, Z., Chen, H., Wang, D., Liu, N., Liu, D., Chen, G., Zhang, Y., Li, D., Li, J., Lian, H., Niu, S., Zhang, L., & Zhang, J. (2020). Characteristics of COVID-19 infection in Beijing. *Journal of Infection*, 80(4), 401–406.
<https://doi.org/10.1016/j.jinf.2020.02.018>
- Tsai, Y., Vogt, T. M., & Zhou, F. (2021). Patient characteristics and costs associated with covid-19-related medical care among medicare fee-for-service beneficiaries. *Annals of Internal Medicine*, 174(8), 1101–1109.
<https://doi.org/10.7326/M21-1102>
- Unicef. (2020). *COVID-19: Frequently asked questions UNICEF*.
<https://www.unicef.org/stories/novel-coronavirus-outbreak-frequently-asked-questions>
- Wahid, L., & Ortel, T. L. (2021). Anticoagulant Therapy in Patients Hospitalized With COVID-19. *JAMA Internal Medicine*, 181(12), 1621.
<https://doi.org/10.1001/jamainternmed.2021.6212>
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - Journal of the American Medical Association*, 323(11), 1061–1069.
<https://doi.org/10.1001/jama.2020.1585>
- WHO. (2020a). *Clinical Management of COVID-19 Interim guidance 27 May 2020 [Internet]*. <https://apps.who.int/iris/handle/10665/332196>
- WHO. (2020b). *Coronavirus disease (COVID-19)*. https://www.who.int/health-topics/coronavirus#tab=tab_1
- WHO. (2020c). *Situation Report – 10*. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200130-sitrep-10-ncov.pdf?sfvrsn=d0b2e480_2
- WHO. (2022a). *WHO Coronavirus (COVID-19)*.
<https://covid19.who.int/region/searo/country/id>
- WHO. (2022b). *Indonesia : WHO Coronavirus Disease (COVID-19)*.
<https://covid19.who.int/region/searo/country/id>
- Widjaja, J. T., Kwee, L., Giantara, A. K., Subagiyo, H. A., Edwin, C., & Putri, R. L. (2021). Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia Characteristics of Inpatient Covid-19 Patients at Immanuel Hospital Bandung, Indonesia. In *Journal of Medicine and Health Karakteristik Pasien COVID-19 Rawat* (Vol. 3, Issue 2).
- Wong, C. K. H., Lau, K. T. K., Au, I. C. H., Xiong, X., Lau, E. H. Y., & Cowling, B. J. (2022). Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With

- Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases*, 74(8), 1450–1458. <https://doi.org/10.1093/cid/ciab631>
- Yacouba, A., Olowo-okere, A., & Yunusa, I. (2021). Repurposing of antibiotics for clinical management of COVID-19: a narrative review. *Annals of Clinical Microbiology and Antimicrobials*, 20(1), 37. <https://doi.org/10.1186/s12941-021-00444-9>
- Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*, 8(5), 475–481. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)
- Zhang, T., Wu, Q., & Zhang, Z. (2020a). Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology*, 30(7), 1346-1351.e2. <https://doi.org/10.1016/j.cub.2020.03.022>
- Zhang, T., Wu, Q., & Zhang, Z. (2020b). Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology*, 30(7), 1346-1351.e2. <https://doi.org/10.1016/j.cub.2020.03.022>
- Zhao, X. Y., Xu, X. X., Yin, H. Sen, Hu, Q. M., Xiong, T., Tang, Y. Y., Yang, A. Y., Yu, B. P., & Huang, Z. P. (2020). Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: A retrospective study. *BMC Infectious Diseases*, 20(1). <https://doi.org/10.1186/s12879-020-05010-w>
- Zhong, H., Wang, Y., Zhang, Z.-L., Liu, Y.-X., Le, K.-J., Cui, M., Yu, Y.-T., Gu, Z.-C., Gao, Y., & Lin, H.-W. (2020). Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. *Pharmacological Research*, 157, 104872. <https://doi.org/10.1016/j.phrs.2020.104872>
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, 395(10229), 1054–1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
- Zhu, X., Ge, Y., Wu, T., Zhao, K., Chen, Y., Wu, B., Zhu, F., Zhu, B., & Cui, L. (2020). Co-infection with respiratory pathogens among COVID-2019 cases. *Virus Research*, 285. <https://doi.org/10.1016/j.virusres.2020.198005>